Tag: Opioid use disorder treatment

Sublocade, an extended-release buprenorphine injection, carries a boxed warning from the FDA for the severe and potentially fatal risk of respiratory depression when combined with other central nervous system (CNS) depressants. This makes understanding **what medications can you not take with Sublocade** a critical component of patient safety.

The FDA has approved three primary medications for treating opioid use disorder (OUD): buprenorphine, methadone, and naltrexone. If you or a loved one is seeking treatment, understanding what medication is similar to buprenorphine can help identify suitable alternatives as part of a comprehensive care plan.

Recent research from the NIH indicates that patients taking higher daily doses of buprenorphine, specifically more than 16 mg to 24 mg, may experience better treatment retention and outcomes. The question, **is 20 mg of buprenorphine a lot?**, depends heavily on the individual's history, tolerance, and overall treatment plan for opioid use disorder.

Unlike some other injectable treatments for opioid use disorder, Brixadi (buprenorphine) does not need to be refrigerated and should be stored at controlled room temperature. Understanding the correct storage requirements is vital to ensuring the medication's stability and effectiveness for treating moderate to severe opioid use disorder.